Sequential Treatments with Tongsai and Bufei Yishen Granules Reduce Inflammation and Improve Pulmonary Function in Acute Exacerbation-Risk Window of Chronic Obstructive Pulmonary Disease in Rats

Table 1

Protocol for treatments during the acute exacerbation and risk window phases in COPD rats.

Group	⁢AE phase				RW phase
	(Day −1, 0, Day 2 to Day 6)				(Day 7 to Day 16)
	NS	TSG	MXF	STL	NS	BYG	STL
Control	+	−	−	−	+	−	−
COPD	+	−	−	−	+	−	−
AECOPD	+	−	−	−	+	−	−
TSG/NS	−	+	−	−	+	−	−
MXF+STL/NS	−	−	+	+	+	−	−
TSG/BYG	−	+	−	−	−	+	−
MXF+STL/STL	−	−	+	+	−	−	+
TSG+MXF+STL/BYG+STL	−	+	+	+	−	+	+

Note: +: treated with this medicine; −: not treated with this medicine. AE: acute exacerbation; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; BYG: Bufei Yishen Granule; COPD: chronic obstructive pulmonary disease; MXF: moxifloxacin; NS: normal saline; RW: risk window; TSG: Tongsai Granule; STL: salbutamol.